Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (321-330 of 512) with videos related to

Pageof 52
Sort By:
Journal for Immunotherapy of Cancer|June 23, 2026
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLCMatthieu Roulleaux-Dugage, Andrey Yurchenko, Sergey Nikolaev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLCLuc Friboulet, Daniel Barrios-Gonzales, Frédéric Commo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2020
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF<sup>V600E</sup> non-small cell lung cancerFrancesco Facchinetti, Ludovic Lacroix, Laura Mezquita, et al.
Clinical Lung Cancer|September 30, 2022
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France StudyPierre Mordant, Solenn Brosseau, Bernard Milleron, et al.
The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
JCI Insight|May 5, 2022
Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explantsTala Tayoun, Vincent Faugeroux, Marianne Oulhen, et al.
Cancers|December 17, 2020
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung CancerArthur Geraud, Laura Mezquita, Edouard Auclin, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncologyEmily Alouani, Ariane Laparra, Audrey Perret, et al.
Pageof 52

Showing results (321-330 of 512) with videos related to

Sort By:
Pageof 52
Journal for Immunotherapy of Cancer|June 23, 2026
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLCMatthieu Roulleaux-Dugage, Andrey Yurchenko, Sergey Nikolaev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLCLuc Friboulet, Daniel Barrios-Gonzales, Frédéric Commo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2020
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF<sup>V600E</sup> non-small cell lung cancerFrancesco Facchinetti, Ludovic Lacroix, Laura Mezquita, et al.
Clinical Lung Cancer|September 30, 2022
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France StudyPierre Mordant, Solenn Brosseau, Bernard Milleron, et al.
The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
JCI Insight|May 5, 2022
Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explantsTala Tayoun, Vincent Faugeroux, Marianne Oulhen, et al.
Cancers|December 17, 2020
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung CancerArthur Geraud, Laura Mezquita, Edouard Auclin, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncologyEmily Alouani, Ariane Laparra, Audrey Perret, et al.
Pageof 52